<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720716</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310C301</org_study_id>
    <nct_id>NCT04720716</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC</brief_title>
  <official_title>A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, controlled, multicenter Phase III study to evaluate the&#xD;
      effectiveness and safety of IBI310 combined with sintilimab and sorafenib in patients with&#xD;
      locally advanced or metastatic HCC who have not previously received systemic therapy, are&#xD;
      unsuitable for radical surgical resection or local treatment, or have had progressive disease&#xD;
      after surgical resection or local treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Objective response rate (ORR) in two arms based on RECIST V1.1 by the IRRC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Progression-free survival (PFS) in two arms based on RECIST V1.1 by the IRRC and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Duration of response(DOR) in two arms based on RECIST V1.1 by the IRRC and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Disease control rate(DCR) in two arms based on RECIST V1.1 by the IRRC and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Time to progression(TTP) in two arms based on RECIST V1.1 by the IRRC and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response(TTR)</measure>
    <time_frame>up to 24 months after randomization</time_frame>
    <description>Time to response(TTR) in two arms based on RECIST V1.1 by the IRRC and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of Treatment-Emergent Adverse Events</measure>
    <time_frame>up to 24 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab combined with IBI310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>IBI310 IV d1, Q3W for up to 4 cycles</description>
    <arm_group_label>Sintilimab combined with IBI310</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>sintilimab IV d1, Q3W</description>
    <arm_group_label>Sintilimab combined with IBI310</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400mg po</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically/cytologically confirmed hepatocellular carcinoma, or liver cirrhosis&#xD;
             meeting the clinical diagnostic criteria;&#xD;
&#xD;
          2. ECOG performance status score of 0 or 1 point;&#xD;
&#xD;
          3. No systemic antitumor treatment for hepatocellular carcinoma before the first&#xD;
             administration;&#xD;
&#xD;
          4. Barcelona Clinic Liver Cancer stage C, or Stage B not suitable for radical surgery&#xD;
             and/or local treatment;&#xD;
&#xD;
          5. At least 1 measurable lesion according to RECIST V1.1);&#xD;
&#xD;
          6. Child-Pugh:â‰¤6&#xD;
&#xD;
          7. Adequate organ and bone marrow function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,&#xD;
             cholangiocarcinoma components in tumor tissues.&#xD;
&#xD;
          2. Have a history of hepatic encephalopathy or have a history of liver transplantation.&#xD;
&#xD;
          3. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial&#xD;
             effusion.&#xD;
&#xD;
          4. Central nervous system (CNS) metastasis.&#xD;
&#xD;
          5. Uncontrolled high blood pressure, systolic blood pressure &gt;140mmHg or diastolic blood&#xD;
             pressure &gt;90mmHg after optimal medical treatment.&#xD;
&#xD;
          6. Local treatment for liver lesions within 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Universtiy Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>haiyun Zuo</last_name>
    <phone>021-31016866</phone>
    <email>haiyun.zuo@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan Universtiy Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan</last_name>
      <phone>021-64041990</phone>
      <email>Fan.jia@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

